Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.85 |
| ▸ | SLC11A2 | P49281 | 11/20 | 0.55 |
| ▸ | CYBB | P04839 | 1/20 | 0.50 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.50 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | ALKBH3 | Q96Q83 | 6/20 | 0.48 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2571554 | 0.92 | KDM4E (1.00) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL15258771 | 0.88 | KDM4E (0.81) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL15258790 | 0.88 | KDM4E (0.81) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL2569372 | 0.87 | KDM4E (0.76) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL15258802 | 0.86 | KDM4E (0.80) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL2567480 | 0.85 | KDM4E (0.78) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL15258848 | 0.85 | KDM4E (0.78) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL2568228 | 0.85 | KDM4E (0.78) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL2565049 | 0.84 | KDM4E (0.76) | KDM4ESLC11A2CYBBNOX4NOX1 | |
| SCHEMBL15258869 | 0.82 | KDM4E (0.76) | KDM4ESLC11A2CYBBNOX4NOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2382205-B1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI SA (FR) | 2014-04-23 | — | — | EP | claimed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | claimed |
| EP-2382205-B1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI SA (FR) | 2014-04-23 | — | — | EP | disclosed |
| US-8541455-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-12-01 | — | — | US | disclosed |
| EP-2382205-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076524-A2 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294788-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF AS HIF ACTIVATORS | HIF1AN, HIF1A, EGLN2 | KDM4E 1006/4885SLC11A2 2058/4885CYBB 1376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.